Aligos Therapeutics has entered into an exclusive licensing agreement with Xiamen Amoytop Biotech, granting the Chinese biopharmaceutical company the rights to develop and commercialize pevifoscorvir sodium for the treatment of chronic hepatitis B virus (HBV) infection across Greater China. This significant deal, which includes Hong Kong, Macau, Mainland China, and Taiwan, targets a region grappling with a substantial burden of HBV, affecting over 90 million individuals. The collaboration underscores a strategic move to accelerate access to innovative HBV therapies in a critical global market.
Strategic Partnership to Address a Significant Unmet Need in HBV Treatment
The agreement positions pevifoscorvir sodium, a potential first-in-class capsid assembly modulator (CAM-E), as a promising new therapeutic option for the vast HBV-infected population in Greater China. Chronic HBV infection remains a major global health challenge, leading to serious liver diseases such as cirrhosis and hepatocellular carcinoma. The current standard of care, while effective in suppressing viral replication, often requires lifelong treatment and does not achieve a functional cure for most patients. This licensing deal signifies a commitment to explore novel mechanisms of action to address the limitations of existing therapies.
Under the terms of the agreement, Aligos Therapeutics will receive an initial upfront milestone payment of $25 million from Xiamen Amoytop Biotech. Beyond this initial sum, Aligos is eligible to secure up to an additional $420 million in future milestone payments, contingent upon the successful achievement of clinical, regulatory, and commercial targets. Furthermore, Aligos will be entitled to receive tiered, high single-digit royalties on the net sales of pevifoscorvir sodium within the licensed territories. This financial structure incentivizes both parties to collaboratively drive the program towards successful market penetration.
Crucially, Aligos Therapeutics will retain all rights for the development and commercialization of pevifoscorvir sodium outside of Greater China, including key markets such as Europe, Japan, South Korea, and the United States. This retention allows Aligos to continue pursuing its global development strategy for the drug independently in these regions, while leveraging Amoytop’s expertise and market access within China. Aligos will also be responsible for conducting clinical trials in Greater China, ensuring alignment with local regulatory requirements and patient needs.
Pevifoscorvir Sodium: A Novel Approach to HBV Therapy
Pevifoscorvir sodium represents a novel therapeutic strategy targeting a critical stage in the HBV lifecycle. As a capsid assembly modulator, it disrupts the formation of the viral capsid, a protein shell that encloses the viral genetic material. By interfering with this essential process, pevifoscorvir sodium aims to prevent the assembly of new infectious viral particles, thereby reducing viral load and potentially offering a more comprehensive approach to viral suppression. This mechanism of action differs from nucleos(t)ide analogs, which primarily inhibit viral DNA polymerase.
The drug is currently being evaluated in the Phase II B-SUPREME study, a pivotal trial designed to assess its efficacy and safety compared to tenofovir disoproxil fumarate (TDF), a widely used nucleoside analog. The B-SUPREME study is generating crucial data that will inform the future development path of pevifoscorvir sodium. The second interim analysis of this study is anticipated in the second half of 2026, with final top-line data expected in 2027. These timelines suggest a methodical and data-driven approach to advancing the drug through clinical development.
Strategic Rationale and Financial Implications for Aligos Therapeutics
The licensing deal with Xiamen Amoytop Biotech is expected to have a significant positive impact on Aligos Therapeutics’ financial standing. The company projects that this agreement will extend its current cash, cash equivalents, and investments runway into the fourth quarter of 2026, based on its existing operating plan. This extended financial runway provides Aligos with greater flexibility to advance its pipeline programs, including ongoing clinical trials and research initiatives, without immediate pressure for further fundraising.
The upfront payment of $25 million provides immediate capital, while the potential for substantial milestone payments and royalties offers a long-term revenue stream that could significantly enhance shareholder value. This transaction also validates Aligos’ scientific approach and the potential of pevifoscorvir sodium as a differentiated therapy for chronic HBV.
Xiamen Amoytop Biotech’s Strategic Vision and Commitment
Xiamen Amoytop Biotech, a prominent player in the Chinese biopharmaceutical landscape, has expressed enthusiasm for the deepened partnership with Aligos. Sun Li, Chairman and CEO of Xiamen Amoytop Biotech, highlighted Aligos’ position at the forefront of HBV innovation and emphasized their belief in pevifoscorvir sodium’s potential to transform chronic HBV suppression.
"Aligos is at the forefront of HBV innovation, and we are pleased to deepen our partnership with this outstanding team," stated Sun Li. "We believe pevifoscorvir sodium has the potential to transform chronic HBV suppression, and we are proud to license this important program for Greater China."
Amoytop Biotech’s strategic interest in pevifoscorvir sodium aligns with its broader portfolio development and its commitment to addressing significant unmet medical needs in China. The company’s existing portfolio includes the Aligos-partnered ASO (antisense oligonucleotide) therapy and the approved PEGBING® therapy, indicating a strategic focus on liver diseases. This new agreement further strengthens Amoytop’s position in the HBV market and opens avenues for exploring combination therapies.
"As we continue to build our portfolio, including the Aligos-partnered ASO and approved PEGBING therapy, we look forward to exploring combination approaches that deliver meaningful benefits to patients across the region," added Sun Li. This forward-looking statement suggests Amoytop’s intent to integrate pevifoscorvir sodium into comprehensive treatment strategies, potentially involving its existing or future therapeutic offerings.
Broader Implications for the HBV Market and Patient Access
The licensing agreement between Aligos and Amoytop Biotech is poised to have significant implications for the HBV treatment landscape in Greater China and potentially beyond. By bringing a novel mechanism of action into a market with a high prevalence of chronic HBV, the partnership aims to offer a much-needed alternative or complementary treatment option.
Increased Competition and Therapeutic Innovation: The introduction of pevifoscorvir sodium is expected to foster increased competition among HBV therapies, driving further innovation and potentially leading to improved treatment outcomes for patients. The CAM-E approach represents a distinct therapeutic strategy, which could be particularly beneficial for patients who do not respond optimally to existing treatments or who experience adverse effects.
Enhanced Patient Access: Amoytop Biotech’s established presence and expertise in the Chinese market are crucial for ensuring the successful development and commercialization of pevifoscorvir sodium. This partnership is anticipated to accelerate the availability of this innovative therapy to the millions of HBV patients in the region who currently have limited treatment options.
Potential for Combination Therapies: As highlighted by Amoytop’s CEO, the integration of pevifoscorvir sodium into combination therapy regimens could unlock new treatment paradigms. Research into combining different therapeutic agents with distinct mechanisms of action is a key area of focus in HBV research, aiming to achieve higher rates of viral suppression, immune control, and functional cure.
Global Development Synergy: While Aligos retains rights outside Greater China, the progress and data generated from the B-SUPREME study and subsequent trials in China can inform and potentially accelerate global development efforts. This collaborative approach leverages regional expertise while maintaining a unified global strategy for the drug.
Regulatory and Commercial Outlook
The closing of the agreement is anticipated within 30 days, subject to the approval of Xiamen Amoytop Biotech’s shareholders. This timeline suggests that the transaction is on a clear path to completion. Following regulatory approval, Amoytop Biotech will be responsible for navigating the complex Chinese regulatory landscape to bring pevifoscorvir sodium to market. The company’s experience with previous drug approvals and commercial launches in China will be instrumental in this process.
The success of pevifoscorvir sodium will ultimately depend on its clinical profile, including its efficacy, safety, and tolerability, as demonstrated in ongoing and future clinical trials. The comparison with TDF in the B-SUPREME study will provide critical insights into its relative benefits. If the drug demonstrates a favorable risk-benefit profile, it has the potential to become a significant treatment option for chronic HBV patients in Greater China and a valuable addition to Aligos Therapeutics’ global pipeline.
Background: The Enduring Challenge of Chronic Hepatitis B
Chronic hepatitis B infection is a persistent global health issue, with an estimated 296 million people living with the disease worldwide, according to the World Health Organization (WHO). The majority of these cases are concentrated in the Western Pacific and African regions. Without effective treatment, chronic HBV infection can lead to severe liver damage, including fibrosis, cirrhosis, and hepatocellular carcinoma (HCC), which is a leading cause of cancer-related deaths globally.
Current treatments for chronic HBV primarily include nucleoside/nucleotide analogs (NUCs) and interferons. While NUCs effectively suppress viral replication and reduce the risk of liver disease progression, they typically do not lead to a functional cure, meaning the virus remains in the body, and treatment is often required for life. Interferons can induce a sustained virological response in a subset of patients but are associated with more significant side effects.
The development of novel therapeutic agents with different mechanisms of action, such as capsid assembly modulators, is crucial for addressing the limitations of current therapies and moving towards a functional cure for HBV. The licensing of pevifoscorvir sodium by Aligos Therapeutics to Amoytop Biotech represents a significant step in this ongoing effort to combat a disease that continues to affect millions worldwide. This collaboration highlights the increasing importance of strategic partnerships between Western and Eastern pharmaceutical companies to accelerate drug development and improve patient access to life-changing medicines.
Leave a Reply